Having demonstrated that a secreted factor from MEK1‐hi tumours has at least moderate anti‐tumour activity, we next tested the immune modulatory potential of MEK1‐hi versus MEK1‐low EVs. The gene discussed is MAP2K1; the disease is neoplasm.